Amikacin: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
No edit summary
Line 1: Line 1:
{{drugbox
{{drugbox
| IUPAC_name = (2''S'')-4-amino-N-[(2''S'',3''S'',4''R'',5''S'')-5-amino-2-<br>[(2''S'',3''R'',4''S'',5''S'',6''R'')-4-amino-3,5-dihydroxy-<br>6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2''R'',3''R'',<br>4''S'',5''R'',6''R'')-6-(aminomethyl)-3,4,5-trihydroxy-<br>oxan-2-yl]oxy-3-hydroxy-cyclohexyl]-2-hydroxy-<br>butanamide
| IUPAC_name = (2''S'')-4-amino-N-[(2''S'',3''S'',4''R'',5''S'')-5-amino-2-<br>[(2''S'',3''R'',4''S'',5''S'',6''R'')-4-amino-3,5-dihydroxy-<br>6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2''R'',3''R'',<br>4''S'',5''R'',6''R'')-6-(aminomethyl)-3,4,5-trihydroxy-<br>oxan-2-yl]oxy-3-hydroxy-cyclohexyl]-2-hydroxy-<br>butanamide
| image = Amikacin.svg
| image = Amikacin.png
| CAS_number = 37517-28-5
| CAS_number = 37517-28-5
| ATC_prefix = D06
| ATC_prefix = D06

Revision as of 17:20, 23 June 2009

Amikacin
Clinical data
Pregnancy
category
  • AU: D
  • US: C (Risk not ruled out)
Routes of
administration
Intramuscular, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding0-11%
Elimination half-life2-3 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H43N5O13
Molar mass585.603 g/mol

WikiDoc Resources for Amikacin

Articles

Most recent articles on Amikacin

Most cited articles on Amikacin

Review articles on Amikacin

Articles on Amikacin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Amikacin

Images of Amikacin

Photos of Amikacin

Podcasts & MP3s on Amikacin

Videos on Amikacin

Evidence Based Medicine

Cochrane Collaboration on Amikacin

Bandolier on Amikacin

TRIP on Amikacin

Clinical Trials

Ongoing Trials on Amikacin at Clinical Trials.gov

Trial results on Amikacin

Clinical Trials on Amikacin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Amikacin

NICE Guidance on Amikacin

NHS PRODIGY Guidance

FDA on Amikacin

CDC on Amikacin

Books

Books on Amikacin

News

Amikacin in the news

Be alerted to news on Amikacin

News trends on Amikacin

Commentary

Blogs on Amikacin

Definitions

Definitions of Amikacin

Patient Resources / Community

Patient resources on Amikacin

Discussion groups on Amikacin

Patient Handouts on Amikacin

Directions to Hospitals Treating Amikacin

Risk calculators and risk factors for Amikacin

Healthcare Provider Resources

Symptoms of Amikacin

Causes & Risk Factors for Amikacin

Diagnostic studies for Amikacin

Treatment of Amikacin

Continuing Medical Education (CME)

CME Programs on Amikacin

International

Amikacin en Espanol

Amikacin en Francais

Business

Amikacin in the Marketplace

Patents on Amikacin

Experimental / Informatics

List of terms related to Amikacin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections. Amikacin works by binding to the bacterial 30S ribosomal subunit, causing misreading of mRNA and leaving the bacterium unable to synthesize proteins vital to its growth.

Administration

Amikacin may be administered once or twice a day but must be given by the intravenous or intramuscular route, which tends to be painful. There is no oral form available. Dosage must be adjusted in people with kidney failure.

Uses

Amikacin is most often used for treating severe, hospital-acquired infections with multidrug resistant Gram negative bacteria such as Pseudomonas aeruginosa, Acinetobacter, and Enterobacter.

Amikacin may be combined with a beta-lactam antibiotic for empiric therapy for people with neutropenia and fever.

Side effects

Side effects of amikacin are similar to other aminoglycosides. Kidney damage and hearing loss are the most important effects. Because of this potential, blood levels of the drug and markers of kidney function (creatinine) may be monitored.

References

  • Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc. 1999 May;74(5):519-28. Review. PMID 10319086

Template:AminoglycosideAntiBiotics Template:SIB th:อะมิกาซิน

Template:WS